Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Oct 26, 2021 7:00am EDT

Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit

Oct 21, 2021 7:00am EDT

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal

Oct 05, 2021 7:00am EDT

Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

Sep 22, 2021 7:00am EDT

Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021

Sep 17, 2021 7:00am EDT

Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences

Sep 09, 2021 7:00am EDT

Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 02, 2021 7:00am EDT

Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study

Aug 26, 2021 7:00am EDT

Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update

Aug 12, 2021 8:00am EDT

Can-Fite Announces $10.0 Million Registered Direct Offering

Aug 05, 2021 9:18am EDT

Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board

  • arrow_back
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding